Leading Chinese vaccine developer CanSino Biologics Inc has inked a deal to test and sell a separate Canadian vaccine candidate as the race for immunisation intensifies globally.
In addition to developing its own vaccine together with the Chinese military, CanSino will partner with Vancouver-based Precision NanoSystems Inc to co-develop another potential vaccine, according to a joint press release.
The Chinese company will conduct testing of Precision’s experimental vaccine and has the right to commercialise it in Asia excluding Japan, said the statement.
Widely viewed as one of the front-runners in the race to
develop a successful vaccine, the new deal adds to CanSino’s chances of being among the first to deliver immunising shots.
Chinese President Xi Jinping has pledged to make any effective vaccine against the coronavirus that is developed by China accessible and affordable globally as a “public good.”
CanSino’s own vaccine is currently in the second of three phases of human testing and is among five Chinese candidates to have reached that advanced stage — more than the US and Europe combined.